Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe
Grigorian-Shamagian, Lilian (Instituto de Salud Carlos III)
Edel, Klaus (Center of Cardiovascular Diseases (Alemanya))
Esteve-Pastor, María Asunción (Instituto Murciano de Investigación Biosanitaria)
Aceña, Álvaro (Universidad Autónoma de Madrid)
Silva, Claudia (USF Cruz de Celas)
Delgado-Silva, Joana (Coimbra Hospital and University Centre)
Ntaios, Georges (University of Thessaly)
Demerouti, Eftychia (Onassis Cardiac Surgery Center)
Brotons, Carlos (Institut d'Investigació Biomèdica Sant Pau)
Universitat Autònoma de Barcelona

Data:	2021
Resum:	The main objective of cardiovascular disease (CVD) prevention is to reduce morbidity and mortality. Despite recommendations on evidence-based pharmacological treatment and lifestyle changes, the control of CV risk factors such as hypertension or dyslipidaemia is not optimal. The use of a CV polypill, including guideline-recommended drugs, as a baseline therapy, may contribute to improving risk factors control either by improving the treatment adherence or by the synergistic effect of its components. The CNIC-Polypill is the first CV polypill approved in Europe as an effective strategy for secondary prevention, which contains acetylsalicylic acid, atorvastatin (in two optional doses), and ramipril (in three optional doses) in a single pill. The present practical clinical document aims to provide a guide for patient management after an acute coronary syndrome (ACS) or with chronic CVD (CCVD) with a strategy based on the CNIC-Polypill, also considering the need to add other therapies for a personalized treatment. The most suitable clinical scenarios for the CNIC-Polypill use are discussed: (a) in patients after an ACS at discharge, (b) in patients with CCVD (chronic coronary syndrome, stroke, or peripheral artery disease) with uncontrolled low-density lipoprotein cholesterol (LDL-c) and/or blood pressure levels and (c) in patients with CCVD with well-controlled risk factors to simplify treatment and reduce polypharmacy in the context of CCVD prevention.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Cardiovascular disease ; Cerebrovascular disease ; Fixed-dose combination ; Polypill ; Secondary prevention
Publicat a:	Frontiers in Cardiovascular Medicine, Vol. 8 (2021) , p. 663361, ISSN 2297-055X

DOI: 10.3389/fcvm.2021.663361
PMID: 34504874

11 p, 1.9 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats